



C4X Discovery

A new dimension in drug discovery

Annual Report and Accounts and Notice of Annual General Meeting

6 November 2015 - C4X Discovery Holdings plc ("C4XD"), a leader in rational drug discovery and design, announces that in accordance with AIM Rule 20, electronic copies of its Annual Report and Accounts for the year ended 31 July 2015 together with the Notice of Annual General Meeting and Form of Proxy are available from the Company's investor relations website at www.c4xdiscovery.com. Hard copies of the 2015 Annual Report and Accounts have been posted to shareholders today.

The Company's Annual General Meeting will be held at 2 p.m. on Tuesday, 8 December 2015 at the offices of C4XD, Manchester One, Portland Street, Manchester, M1 3LD.

For Further information please contact:

C4X Discovery Ltd

Piers Morgan 07912293832
CEO

Zeus Capital Ltd

Dan Bate/ Jonathan Sharp 0161 831 1512

Dominic Wilson 0203 829 5000

FTI Consulting

Matthew Cole / Brett Pollard / Robert Winder / Matthew Moss 020 3727 1000

About C4XD

C4XD (AIM: C4XD) is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4XD's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for rational drug discovery and design, and valuable conformational information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4XD is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. For additional information please go to: www.c4xdiscovery.com